Request Sample Inquiry
Biobanking Market

Biobanking Market

Biobanking Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

142

Base Year:

2021

Date

May - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1607

Segments Covered
  • By Product and Service Equipment, Consumables, Services, Software
  • By Sample Type Blood Products, Human Tissues, Nucleic Acids, Cell Lines, Biological Fluids, Human Waste Products
  • By Application Regenerative Medicine, Life Science Research, Clinical Research
  • By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Forecast YearsForecast Years: 2022 - 2028
Historical YearsHistorical Years: 2016 - 2021
Revenue 2021Revenue 2021: USD 27.1 Billion
Revenue 2028Revenue 2028: USD 44.9 Billion
Revenue CAGRRevenue CAGR (2022 - 2028): 8.8%
Fastest Growing Region Fastest Growing Region (2022 - 2028) Asia Pacific
Largest Region Largest Region (2021): Europe
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst
Biobanking Market Share

Global Biobanking Market

Biobanking Market- By Product and Service, Sample Type, Application, and Region.

Market Synopsis:

The Global Biobanking Market is valued at USD 27.1 Billion in the year 2021 and is projected to reach a value of USD 44.9 Billion by the year 2028. The Global Market is anticipated to grow exhibiting a Compound Annual Growth Rate (CAGR) of 8.8% over the forecast period.

Biobanking Market Size, 2021 To 2028 (USD Billion)

Due to a growing number of diseases and health issues for which no medicinal treatment or vaccination process has been developed, biobanks are being used to collect samples and preserve biological materials for future reference, the Global Biobanking Market is one of the fastest-growing markets in the health and medical sector. Biobanking Market is a technologically advanced market structures that collect and preserve biological data, materials, and samples for future use, as well as gather information about various ailments and study the effects of various diseases, as well as find a treatment. The expansion of the Biobanking Market is attributed to an increase in the number of biobank samples used, which has increased demand for Biobanking equipment.

The amount of research activities and investments made by health-care organizations in research and development activities have further driven demand for the Global Biobanking Market. Not only is Biobanking expanding, but it is also allowing its adjacent markets to expand rapidly. The cryogenic Biobanking industry, for example, is primarily responsible for supplying storage facilities to these market companies so that cells, tissues, blood, and other biological material can be preserved. Furthermore, modern biobanks around the world enable large-scale study of biological and clinical data that has been well-annotated. Growing funding from government organizations, an increase in the application areas of Biobanking samples, and increased investment in research and development activities by healthcare corporations throughout the world are all major growth factors for the Biobanking Market.

Market Segmentation:

The Biobanking Market is segmented on the basis of Product and Service, Application and Sample Type. On the basis of Product and Service, the market is segmented into Equipment, Consumables, Services, Software. On the basis of Sample Type, the market is segmented into Blood Products, Human Tissues, Nucleic Acids, Cell Lines, Biological Fluids and Human Waste Products. On the basis of Application, the market is segmented Regenerative Medicine, Life Science Research, and Clinical Research.

Below tree is interactive. You can click the nodes to get more information.

Based on Sample Type:

In terms of market value and market share, the blood sector led the global market in 2021. Blood sample collection, storage, and dissemination have become more common in developed countries due to an increase in the number of infectious diseases and demand for treatment. Blood samples are important bio specimens since they contain DNA and RNA, which are employed in the conduct of research.

As a result, pharmaceutical companies and academic medical institutes frequently request blood samples from the biobank. In comparison to other sample types, the industry requires 85 percent of blood samples for non-cancerous tests, according to the trans-hit bio database.

Furthermore, the fastest-growing segment in the global market is expected to be cells and tissues. The increased need for cells and tissue samples for research into complicated illnesses including Alzheimer's disease, cancer, and others is driving the rapid expansion. Other samples, such as urine, hair, and many more, are expected to expand more slowly over the predicted period due to reduced demand and distribution.

Based on Application:

The market is divided into three categories based on applications: regenerative medicine, life science research, and clinical research. On the basis of applications, regenerative medicine is predicted to hold the highest share of the market in 2021. Growing regenerative medicine research and the requirement for well-characterized and high-quality bio samples for research are driving this market segment forward. The expansion in sample distribution to academic institutions and pharmaceutical Research and Development (R&D) for clinical applications is attributed with the dominance. Scientists are under pressure from the rising prevalence of complicated diseases and the need for cures.

Furthermore, researchers and pharmaceutical companies from around the world have joined to undertake clinical trials of regenerative therapies for a variety of purposes. Personalized medicine is predicted to play an increasingly important role in human health. As a result, the demand for high-quality samples from biobanks is projected to drive regenerative segment growth in the future years.

Europe Region Dominates the Biobanking Market with the Largest Share

In 2021, Europe dominated the market, with a market share of 36.10%. The presence of well-established biobanks in Nordic countries such as Sweden, Norway, Denmark, and others is credited with this dominance.

According to an article published by Global Engage, a conference and summit organizer for the Life Science and Pharmaceutical industries, almost 40% of Iceland's population has contributed DNA, which is safely and privately preserved in biobanks. As a result of these contributions and the expanding availability of samples, the European biobank market is growing in size.

Furthermore, European pharmaceutical companies' ongoing Research and Development (R&D) activities are one of the factors contributing to the region's larger market share.

Competitive Landscape:

The key players in the Global Biobanking Market include- Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries (Taylor Wharton - U.S.), Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One (Greiner Holding AG - Austria), Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), LabVantage Solutions Inc. (U.S.) and others.

Segmentation of the Global Biobanking Market:

Parameter Details
Segments Covered
  • Product and Service (Equipment, Consumables, Services, Software)
  • Sample Type (Blood Products, Human Tissues, Nucleic Acids, Cell Lines, Biological Fluids, Human Waste Products)
  • Application (Regenerative Medicine, Life Science Research, Clinical Research)
  • Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • Thermo Fisher Scientific Inc. (U.S.)
  • Tecan Group Ltd. (Switzerland)
  • Qiagen N.V. (Germany)
  • Hamilton Company (U.S.)
  • Brooks Automation (U.S.)
  • TTP Labtech Ltd (U.K.)
  • VWR Corporation (U.S.)
  • Promega Corporation (U.S.)
  • Worthington Industries (Taylor Wharton - U.S.)
  • Chart Industries (U.S.)
  • Becton
  • Dickinson and Company (U.S.)
  • Merck KGaA (Germany)
  • Micronic (Netherlands)
  • LVL Technologies GmbH & Co. KG (Germany)
  • Panasonic Healthcare Holdings Co. Ltd (Japan)
  • Greiner Bio One (Greiner Holding AG - Austria)
  • Biokryo GmbH (Germany)
  • Biobank AS (Norway)
  • Biorep Technologies Inc. (U.S.)
  • Cell & Co Bioservices (France)
  • RUCDR infinite biologics (U.S.)
  • Modul-Bio (France)
  • CSols Ltd (U.K.)
  • Ziath (U.K.)
  • LabVantage Solutions Inc. (U.S.)
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis

Biobanking Market to Reach Valuation of USD 44.9 Billion by 2028 - Increase in the number of Genomics research activities for studying diseases, advances in Biobanking, and the growing trend of saving newborns' cord blood stem cells, as well as government and private funding to support regenerative medicine research in Biobanking is expected to drive the Market Growth
From the period of 2022 to 2028, the Global Biobanking Market is expected to reach USD 44.9 Billion in terms of revenue, growing at a Compound Annual Growth Rate (CAGR) of 8.8%. A Biobank is a collection, storage, and distribution facility for human samples such as blood, plasma, serum, urine, tis...
FAQ
Frequently Asked Question
  • The global Biobanking valued at USD 27.1 Billion in 2020 and is expected to reach USD 44.9 Billion in 2028 growing at a CAGR of 8.8%.

  • The prominent players in the market are Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries (Taylor Wharton - U.S.), Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One (Greiner Holding AG - Austria), Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), LabVantage Solutions Inc. (U.S.).

  • The market is project to grow at a CAGR of 8.8% between 2021 and 2028.

  • The driving factors of the Biobanking include

    • Increase in Genomic Research Activities for Studying Diseases

  • Europe was the leading regional segment of the Biobanking in 2020.